secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001503802-25-000006
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Therapeutics director Mansoor Raza Mirza resigns from board effective Sept 8, 2025
--------------------------------------------------------------------------------

- Mansoor Raza Mirza, M.D. resigned from the Board of Directors due to competing professional demands.
- Resignation effective September 8, 2025; not due to any disagreement with the Company.
- Consulting agreement with Mirza Consulting terminated effective September 8, 2025.
- Dr. Mirza also resigning as Chief Oncologist at Copenhagen University National Medical Center effective Oct 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000150380225000006/0001503802-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000150380225000006/kpti-20250905.htm
  HTML page:      https://secwatch.observer/filing/0001503802-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer